Abstract
Background: Metastatic castration sensitive prostate cancer has different modalities of management. However, with the arrival of abiraterone acetate (AA), the management of this condition has changed to a greater extent. Aims and Objectives: As a new molecule its effectiveness and safety are being evaluated in our patient population as a prospective observational study for 18 months. Materials and Methods: This study included 50 patients who were treated with AA according to the treating physician. The overall survival observed at 18 months was 88%. Results: There was a significant decrease in mean serum prostate-specific antigen level with treatment. About 60% of patients were completely adhered to the treatment. About 94% of patients experienced some form of adverse event and 10% of patients died in this study. Though the molecule has adverse effects, the overall survival of the patients has increased. Conclusion: The efficacy of AA was observed consistent with the time in metastatic castration-sensitive prostate cancer patients with manageable adverse events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: National Journal of Physiology, Pharmacy and Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
